Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
1975
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma
1999 Standout
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients
1999 Standout
Mitoxantrone
1991
Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study
1990 StandoutNobel
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
1996 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Current systemic therapy for metastatic melanoma
2009
BTS guidelines for the management of pleural infection in children
2005 Standout
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Phase I — Preliminary phase II trial of iproplatin, a cisplatin analogue
1988
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Clinical applications of quinone-containing alkylating agents
2000
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
Chemotherapy in malignant mesothelioma: a review
1991
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
1995
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature
1997
Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer
1987
Modified ESHAP as Salvage Chemotherapy for Recurrent or Refractory Non-Hodgkin’s Lymphoma: Results of a Single-Center Study of 32 Patients
2002
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
1992
Cardiotoxicity of Chemotherapeutic Agents
2000
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan
2003 Standout
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer
2005
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2003 Standout
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.
1998 Standout
Cisplatin: The first metal based anticancer drug
2019 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
2010 Standout
Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin
1991
Idarubicin
1991
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
2004
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
1991 Standout
Clinical Pharmacology of 5-Fluorouracil
1989 Standout
The status of platinum anticancer drugs in the clinic and in clinical trials
2010 Standout
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
2012 Standout
Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
1975
Adriamycin
1974 Standout
Platinum nephrotoxicity
1978
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Antineoplastic Drugs
1978
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Long-lasting response to cis-platinum in recurrent malignant thymoma
1982
Cardiotoxicity of antitumor agents
1984
The side effects of platinum-based chemotherapy drugs: a review for chemists
2018 Standout
Treatment of Malignant Pericardial Effusion
1994
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
2002 Standout
Nonsurgical management of malignant thymoma
1999
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
2014 Standout
Guidelines on the Diagnosis and Management of Pericardial Diseases Executive SummaryThe Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
2004 Standout
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide
1972
Combination chemotherapy of refractory lymphoma with cis-dichlorodiamineplatinum, vinblastine, and bleomycin
1982
Review: Practical considerations in ovarian cancer chemotherapy
2010
Chemotherapy for advanced gastric cancer
2017 Standout
Mechanisms of Cisplatin Nephrotoxicity
2010 Standout
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.
1996 Standout
Sequential and combination chemotherapy of advanced gastric cancer
1976
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
1985
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
1988
The cardiotoxicity of chemotherapeutic drugs.
1992
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
2014 StandoutNobel
The treatment of malignant pleural effusions
1974
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
A clinicopathologic analysis of adriamycin cardiotoxicity
1973 Standout
New agents in non-small cell lung cancer
1984
Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities
1983
New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease
1976
Epithelial Carcinoma of the Ovary: Current Strategies
1981
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Cis-platinum vestibular toxicity
1981
The Anthracycline Antineoplastic Drugs
1981 Standout
Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.
1985
Cis-diamminedichloroplatinum (II)
1977
Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
1981
Nephrotoxicity Induced by Cancer Chemotherapy With Special Emphasis on Cisplatin Toxicity
1986
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
2005 Standout
Effects of cisplatin on different haemopoietic progenitor cells in mice
1982
The renal toxicity of cancer chemotherapeutic agents
1982
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Malignant thymoma: Renal metastases responding to cis-platinum
1981
Cisplatin
1984 Standout
Works of Talley Rw being referenced
Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893).
1968
Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
1970
Critical analysis of the control of malignant effusions with radioisotopes.
1968
Porfiromycin in the management of epidermoid and transitional cell cancer: a phase II study.
1976
Phase II study of AMSA in lung cancer.
1981
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
1980
5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.
1972
Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study.
1980
Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study.
1974
Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
1982